arrow
K

Kieren J. Mather

Eli Lilly and Company
H指数:57
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies

长效GIPR激动剂LY3537021可降低2型糖尿病患者的体重和空腹血糖:非临床研究与1期随机递增剂量研究

2025-12-120
OAAI
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

Eloralintide,一种选择性降钙素基因相关肽受体激动剂,用于治疗肥胖:一项为期48周的2期、多中心、双盲、随机、安慰剂对照试验

2025-11-060
PRE
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept

Eloralintide (LY3841136),一种新型降钙素基因相关肽受体激动剂用于肥胖症治疗:从发现到临床概念验证

2025-10-160
OAAI
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes

Orforglipron,一种口服非肽类胰高血糖素样肽-1受体激动剂,可改善2型糖尿病中β细胞功能和胰岛素敏感性的指标。

2025-08-140
PRE